Alife Health Inc.

Alife Health Inc. specializes in diagnostic medical devices focused on reproductive health. Their primary product, the Embryo Predict, is designed to evaluate embryo viability and genetic screening parameters during in vitro fertilization (IVF) cycles. This device uses imaging and analytical tools to assess early-stage embryo development and chromosomal abnormalities, helping clinicians make informed decisions about embryo selection.

Alife Health Inc. is based in the United States. While the company operates from there, its devices are subject to global regulatory requirements depending on the market. For example, the Embryo Predict is classified as a Class IIa device under EU regulations and is listed in the EUDAMED database, demonstrating compliance with European Union standards. The company must adhere to both U.S. and international regulatory frameworks to ensure their products meet the necessary safety and performance criteria for each market.

Alife Health Inc.’s Embryo Predict device is listed in the EUDAMED database, which is the European Union’s medical device registry. Listing in EUDAMED is important because it confirms the device’s compliance with EU Medical Device Regulations (MDR) or In Vitro Diagnostic Regulation (IVDR), depending on classification. This transparency helps healthcare providers, regulators, and patients verify the device’s authorized status and regulatory history, ensuring trust in its safety and performance within the EU market.

Alife Health Inc.’s Embryo Predict is classified as a Class IIa medical device under EU regulations. This classification is determined based on factors like the device’s intended use, potential risks, and the level of intervention it involves. Class IIa devices pose moderate risks and require additional scrutiny beyond basic safety checks, including clinical evaluations and conformity assessments by a Notified Body. This classification ensures that the device meets stringent requirements for performance, safety, and traceability before it can be placed on the EU market.